Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-13
2007-11-13
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S229200, C514S230500, C514S312000, C514S333000, C514S375000, C514S378000, C544S002000, C544S105000, C546S153000, C546S158000, C546S280100, C548S159000, C548S247000, C548S527000, C549S023000
Reexamination Certificate
active
10595997
ABSTRACT:
Compounds of formula (I):and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example asthma or chronic obstructive pulmonary disease (COPD).
REFERENCES:
patent: 2918408 (1959-12-01), Biel
patent: 4353365 (1982-10-01), Hallworth et al.
patent: 4778054 (1988-10-01), Newell et al.
patent: 4811731 (1989-03-01), Newell et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 5035237 (1991-07-01), Newell et al.
patent: 5590645 (1997-01-01), Davies et al.
patent: 5860419 (1999-01-01), Davies et al.
patent: 5873360 (1999-02-01), Davies et al.
patent: 6321747 (2001-11-01), Dmitrovic et al.
patent: 6632666 (2003-10-01), Baust et al.
patent: 3524990 (1986-01-01), None
patent: 69715 (1983-01-01), None
patent: 162576 (1985-11-01), None
patent: 220054 (1987-04-01), None
patent: 0303465 (1989-02-01), None
patent: 0947498 (1999-10-01), None
patent: 2064336 (1981-06-01), None
patent: 2129691 (1984-05-01), None
patent: 2165542 (1986-04-01), None
patent: 2169265 (1986-07-01), None
patent: 2178965 (1987-02-01), None
patent: 2230523 (1990-10-01), None
patent: 2242134 (1991-09-01), None
patent: WO99/16766 (1999-04-01), None
patent: WO99/47505 (1999-09-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO 01/13953 (2001-03-01), None
patent: WO 02/066422 (2002-08-01), None
patent: WO 03/024439 (2003-03-01), None
Fujii et al., “Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen,”J Pharmacol Exp Ther284(1):162 (1998).
Landells et al., “Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294A inhibits ex-vivo agonist-induced-cell activation,”Eur Resp J(/annu Cong Eur Resp Soc, Geneva) 12(Suppl. 28) Abst P2393 (Sep. 1998).
Apperley et al., “Selectivity of Beta-adrenoceptor agonists and antagonists on bronchial, skeletal, vascular and cardiac muscle in the anaesthetized cat,”British Journal of Pharmacology57(2):235-246 (1976).
Glaxo Group Limited
O'Sullivan Peter
Smith Robert J.
LandOfFree
Benzothiophen and thiochrone containing phenethanolamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzothiophen and thiochrone containing phenethanolamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiophen and thiochrone containing phenethanolamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3844321